Framework Journal · one stock, one dated entry

Recorded 2025-12-31 · Permanent

Aspire Biopharma Holdings Inc ASBP

Outside both standards

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

In plain words · Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States.

The label
Accumulation

read at $6.24

Aspire Biopharma Holdings Inc holds its Accumulation at $6.24.

PHINPOOPSC
  • PHPhase · the trend structure carries the Accumulation label
  • INInsiders · no filings inside 60 days, left as found
  • POPositioning · no disclosures inside 60 days, left as found
  • OPOptions · no verdict drawn today, left as found
  • SCScreen · does not pass the values gate
  • edge confirmed
  • edge broken
  • edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2025-12-31
PhaseAccumulation
Quantitative stateElevated stress, defensive posture warranted, held for 15 days
Price$6.24
ValuationN/A trailing · N/A forward price to earnings
Values screenFAIL · score 70.0
Beta0.15

The business, in plain words · what the numbers mean

The fundamentals · plain-English read
Profit margin0.0%
currently unprofitable
Debt to equity0.39
minimal debt — a conservative balance sheet
Current ratio2.26
comfortably covers its short-term bills
Beta0.15
barely tracks the market's swings
Market cap$8M

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Plain-English interpretation of our own screen data. Analysis, not advice.

Related securities · others in ASBP's space worth a look

RNAZ TransCode Therapeutics Inc JUNS Jupiter Neurosciences Inc BCAB BioAtla, Inc. BOLT Bolt Biotherapeutics Inc IMNN Imunon Inc QNRX Quoin Pharmaceuticals Ltd ADR

Screened names in the same industry · explore each on its own page.

The trader read · the latest dated commentary

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 25.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 19%. Entered 2026-07-21 · Markup

The dated journal · newest first, never edited

2026-07-21 Markup $6.24 +25.8% Entry 5

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 25.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 19%.

2026-07-18 Markup $4.96 +0.0% Entry 4

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 19%.

2026-07-17 Markup $4.96 +0.0% Entry 3

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 19%.

2026-07-03 Markup $4.96 +0.0% Entry 2

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.

2026-07-02 Markup $4.96 Entry 1

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $5.52 +5.6% · $1,056 +5.6%
2 months $1.06 +450.0% · $5,500 +450.0%
3 months $1.13 +418.2% · $5,182 +418.2%
6 months $4.20 +38.8% · $1,388 +38.8%
1 year $15.08 -61.3% · $387 -61.3%
2 years $456.00 -98.7% · $13 -98.7%
3 years $415.60 -98.6% · $14 -98.6%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever ASBP does next, these words stay.

Aspire Biopharma Holdings Inc · ASBP · Accumulation · $6.24
Recorded 2025-12-31 · before the outcome · scored mechanically

All of today's entries See the running score

Get our weekly market brief free.